Reneo Pharmaceuticals IncNASDAQ:RPHM
- LAST PRICE1.6750
- TODAY'S CHANGE (%)-0.0150 (-0.8876%)
- Bid / Lots1.6500/ 12
- Ask / Lots1.7100/ 62
- Open / Previous Close1.6700 / 1.6900
- Day Range
- 52 Week Range
- Volume78,144
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPHM |
|---|---|---|
| 09:32 ET | 2002 | 1.69 |
| 09:34 ET | 1500 | 1.69 |
| 09:39 ET | 200 | 1.7 |
| 09:43 ET | 1500 | 1.69 |
| 09:45 ET | 300 | 1.7 |
| 09:54 ET | 100 | 1.7 |
| 09:56 ET | 1220 | 1.705 |
| 09:57 ET | 1000 | 1.72 |
| 10:06 ET | 100 | 1.7 |
| 10:08 ET | 800 | 1.7 |
| 10:17 ET | 100 | 1.7 |
| 10:19 ET | 4460 | 1.7 |
| 10:21 ET | 100 | 1.705 |
| 10:30 ET | 500 | 1.69 |
| 10:33 ET | 527 | 1.68 |
| 10:39 ET | 100 | 1.68 |
| 10:42 ET | 1500 | 1.67 |
| 10:46 ET | 1900 | 1.65 |
| 10:48 ET | 2200 | 1.66 |
| 10:50 ET | 210 | 1.66 |
| 10:55 ET | 2714 | 1.67 |
| 11:04 ET | 200 | 1.66 |
| 11:13 ET | 100 | 1.68 |
| 11:15 ET | 1223 | 1.68 |
| 11:18 ET | 105 | 1.68 |
| 11:20 ET | 100 | 1.68 |
| 11:31 ET | 900 | 1.67 |
| 11:38 ET | 1052 | 1.6712 |
| 11:42 ET | 1800 | 1.67 |
| 11:44 ET | 300 | 1.67 |
| 11:51 ET | 100 | 1.67 |
| 11:56 ET | 1168 | 1.67 |
| 12:00 ET | 567 | 1.67 |
| 12:02 ET | 700 | 1.68 |
| 12:09 ET | 996 | 1.675 |
| 12:12 ET | 1072 | 1.67 |
| 12:23 ET | 984 | 1.67 |
| 12:25 ET | 200 | 1.675 |
| 12:34 ET | 1173 | 1.67 |
| 12:36 ET | 3604 | 1.675 |
| 12:45 ET | 1000 | 1.67 |
| 12:56 ET | 1144 | 1.67 |
| 01:08 ET | 1084 | 1.67 |
| 01:10 ET | 100 | 1.67 |
| 01:17 ET | 1300 | 1.67 |
| 01:24 ET | 100 | 1.69 |
| 01:28 ET | 100 | 1.67 |
| 01:42 ET | 300 | 1.67 |
| 01:44 ET | 100 | 1.67 |
| 02:06 ET | 100 | 1.67 |
| 02:09 ET | 1464 | 1.69 |
| 02:11 ET | 379 | 1.68 |
| 02:15 ET | 100 | 1.685 |
| 02:24 ET | 100 | 1.68 |
| 02:26 ET | 100 | 1.685 |
| 02:47 ET | 100 | 1.685 |
| 03:03 ET | 100 | 1.69 |
| 03:18 ET | 621 | 1.68 |
| 03:30 ET | 100 | 1.67 |
| 03:45 ET | 3427 | 1.68 |
| 03:50 ET | 100 | 1.68 |
| 03:52 ET | 3436 | 1.67 |
| 03:54 ET | 200 | 1.67 |
| 03:56 ET | 500 | 1.67 |
| 03:57 ET | 2073 | 1.67 |
| 03:59 ET | 4395 | 1.675 |
Mar 28, 2024
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update, from 7:35AM ET on Thursday Mar 28, 2024 by Dow Jones
7:35AM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update, from 7:35AM ET on Thursday Mar 28, 2024 by Dow Jones
7:35AM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 25, 2024
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors, from 7:00AM ET on Monday Mar 25, 2024 by Dow Jones
7:00AM ET on Monday Mar 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Reneo Pharmaceuticals Inc | 56.5M | -0.7x | --- |
Immix Biopharma Inc | 56.2M | -2.6x | --- |
OKYO Pharma Ltd | 45.9M | -0.1x | --- |
Oncolytics Biotech Inc | 80.4M | -3.5x | --- |
AVROBIO Inc | 53.8M | 4.4x | --- |
Intensity Therapeutics Inc | 53.5M | -4.7x | --- |
Company Information
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Contact Information
- Headquarters
- 18575 Jamboree Road, Suite 275-SIRVINE, CA, United States 92612
- Phone
- 858-283-0280
- Fax
- 302-674-5266
Executives
- Executive Chairman of the Board
- Michael Grey
- President, Chief Executive Officer, Director
- Gregory Flesher
- Co-Founder, Director
- Niall O'Donnell
- Chief Operating Officer
- Michael Cruse
- Chief Medical Officer
- Alejandro Dorenbaum
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $56.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.52 |
Book Value | $2.65 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
